Stock Track | GSK Soars 5.31% in Pre-Market on Strong Q2 Earnings Beat and Positive Oncology Pipeline Updates

Stock Track07-28

GlaxoSmithKline PLC (GSK) shares surged 5.31% in pre-market trading Tuesday, driven by a robust second-quarter earnings report that handily beat analyst expectations and promising pipeline news.

The company reported adjusted earnings per share of $1.35, surpassing the consensus estimate of $1.27 by 6.3%, while quarterly sales of $11.28 billion topped the $10.79 billion forecast. The results represent a nearly 9% increase in earnings and a 5.8% rise in sales compared to the same period last year. GSK also reaffirmed its 2026 guidance, expecting core EPS growth of 7% to 9% and turnover growth of 3% to 5%.

Adding to the positive momentum, GSK’s licensor Hansoh Pharma reported positive phase III data from the ARTEMIS-011 trial of risvantinostat, a B7-H3 targeted drug, in osteosarcoma, bolstering confidence in the company’s oncology pipeline. The company also announced a new cost-cutting plan and a ‘Accelerate Growth’ program, alongside plans to build a new R&D center in Cambridge, further supporting long-term growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134029936?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134029936","market":"nz","top_or_hot":-1,"title":"Stock Track | GSK Soars 5.31% in Pre-Market on Strong Q2 Earnings Beat and Positive Oncology Pipeline Updates","media":"Stock Track","content":"<p>GlaxoSmithKline PLC (GSK) shares surged 5.31% in pre-market trading Tuesday, driven by a robust second-quarter earnings report that handily beat analyst expectations and promising pipeline news.</p><p>The company reported adjusted earnings per share of $1.35, surpassing the consensus estimate of $1.27 by 6.3%, while quarterly sales of $11.28 billion topped the $10.79 billion forecast. The results represent a nearly 9% increase in earnings and a 5.8% rise in sales compared to the same period last year. GSK also reaffirmed its 2026 guidance, expecting core EPS growth of 7% to 9% and turnover growth of 3% to 5%.</p><p>Adding to the positive momentum, GSK’s licensor Hansoh Pharma reported positive phase III data from the ARTEMIS-011 trial of risvantinostat, a B7-H3 targeted drug, in osteosarcoma, bolstering confidence in the company’s oncology pipeline. The company also announced a new cost-cutting plan and a ‘Accelerate Growth’ program, alongside plans to build a new R&D center in Cambridge, further supporting long-term growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GSK Soars 5.31% in Pre-Market on Strong Q2 Earnings Beat and Positive Oncology Pipeline Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GSK Soars 5.31% in Pre-Market on Strong Q2 Earnings Beat and Positive Oncology Pipeline Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-28 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GlaxoSmithKline PLC (GSK) shares surged 5.31% in pre-market trading Tuesday, driven by a robust second-quarter earnings report that handily beat analyst expectations and promising pipeline news.</p><p>The company reported adjusted earnings per share of $1.35, surpassing the consensus estimate of $1.27 by 6.3%, while quarterly sales of $11.28 billion topped the $10.79 billion forecast. The results represent a nearly 9% increase in earnings and a 5.8% rise in sales compared to the same period last year. GSK also reaffirmed its 2026 guidance, expecting core EPS growth of 7% to 9% and turnover growth of 3% to 5%.</p><p>Adding to the positive momentum, GSK’s licensor Hansoh Pharma reported positive phase III data from the ARTEMIS-011 trial of risvantinostat, a B7-H3 targeted drug, in osteosarcoma, bolstering confidence in the company’s oncology pipeline. The company also announced a new cost-cutting plan and a ‘Accelerate Growth’ program, alongside plans to build a new R&D center in Cambridge, further supporting long-term growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"","article_id":"1134029936","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134029936","pubTimestamp":1785245726,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GlaxoSmithKline PLC (GSK) shares surged 5.31% in pre-market trading Tuesday, driven by a robust second-quarter earnings report that handily beat analyst expectations and promising pipeline news.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克"},"translate_title":"股票跟踪 | 葛兰素史克 (GSK) 因第二季度盈利强劲和肿瘤管道更新积极，盘前股价飙升 5.31%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1},"content_text":"GlaxoSmithKline PLC (GSK) shares surged 5.31% in pre-market trading Tuesday, driven by a robust second-quarter earnings report that handily beat analyst expectations and promising pipeline news.The company reported adjusted earnings per share of $1.35, surpassing the consensus estimate of $1.27 by 6.3%, while quarterly sales of $11.28 billion topped the $10.79 billion forecast. The results represent a nearly 9% increase in earnings and a 5.8% rise in sales compared to the same period last year. GSK also reaffirmed its 2026 guidance, expecting core EPS growth of 7% to 9% and turnover growth of 3% to 5%.Adding to the positive momentum, GSK’s licensor Hansoh Pharma reported positive phase III data from the ARTEMIS-011 trial of risvantinostat, a B7-H3 targeted drug, in osteosarcoma, bolstering confidence in the company’s oncology pipeline. The company also announced a new cost-cutting plan and a ‘Accelerate Growth’ program, alongside plans to build a new R&D center in Cambridge, further supporting long-term growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134029936","isCrawlerRequest":true}